Breaking
Monday, June 29, 2026

Diabetes News

🇺🇸 FDA

FDA breaking news and regulatory updates for BD, investors, and analysts

Showing 1–12 of 17 articles

Critical impact NewsJun 15, 2026

FDA expands Tzield to certain pediatric patients with recent Stage 3 T1D

FDA · diabetes · 5 min

Dr. Sarah Mitchell
High impact NewsJun 13, 2026

FDA Clears First OTC CGM for Children: Dexcom Expands Stelo

FDA · diabetes · 4 min

Dr. Sarah Mitchell
High impact NewsJun 12, 2026

Chile warning labels on food: new evidence on efficacy and obesity risk

diabetes · 5 min

Dr. Sarah Mitchell
Critical impact NewsJun 7, 2026

GLP-1 usage statistics show broad uptake and mixed clinical signals

GLP-1 · 5 min

Dr. Sarah Mitchell
High impact NewsJun 7, 2026

MariTide Phase 2 obesity data show up to 20% weight loss at one year

obesity · 5 min

Dr. Sarah Mitchell
Critical impact NewsJun 7, 2026

MariTide Phase 2: Amgen reports up to 20% weight loss at one year

obesity · 5 min

Dr. Sarah Mitchell
Critical impact NewsMay 4, 2026

FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market

FDA · Diabetes/Endocrinology · 4 min

Dr. Emily Carter
Critical impact NewsMay 2, 2026

Novo Nordisk's Oral Ozempic Becomes First FDA-Approved Pill GLP-1 for Type 2 Diabetes with Cardiovascular Protection

FDA · Type 2 diabetes with cardiovascular risk reduction · 3 min

James Chen, PharmD
High impact NewsApr 27, 2026

GLP-1 Eating Disorder Risk: What You Need to Know

FDA · Obesity and type 2 diabetes · 4 min

Dr. Hannah O'Connor
High impact NewsApr 27, 2026

Ascletis Completes Enrollment for ASC30 Oral GLP-1 Diabetes Drug Phase II Trial

3 min

Dr. Natalie Hughes
High impact NewsApr 27, 2026

Ascletis Completes Enrollment in Phase II Trial of ASC30 Oral GLP-1 Diabetes Drug

2 min

Dr. Natalie Hughes
High impact NewsApr 23, 2026

Novo Nordisk's Oral Semaglutide Shows Promise as First GLP-1 Therapy for Children with Type 2 Diabetes

Type 2 Diabetes · 4 min

Dr. Emily Carter